AllDocs -> cancers

[Frontiers in Bioscience 2, g20-26, March 15, 1997] 20 CHEMOTHERAPY OF ADVANCED OVARIAN CANCER Martoni A. 1 , Cacciari N., Angelelli B., Zamagni C., Pannuti F. Med. Oncology Division, S.Orsola -Malpighi Hospital, Bologna, Italy TABLE OF CONTENTS 1. Abstract 2. Introduction 3. Chemotherapy of ovarian cancer with platinum-compounds 3.1. Cis-platinum - based chemotherapy 3.2. Carboplatin-based chemotherapy 4. Taxol 4.1. Chemotherapy of ovarian cancer with taxol 4.2. Combination taxol-carboplatin 5. References 1. ABSTRACT Majority of ovarian cancer patients have advanced disease (stage III or IV) at diagnosis and the prognosis of these patients is poor in spite of aggressive surgery. Therefore chemotherapy has gained a fundamental role in the therapeutic approach of ovarian cancer . Platinum ...

[Frontiers in Bioscience 1, g24-29, 1 December 1996] 24 POTENTIAL ROLE OF GROWTH FACTORS IN OVARIAN CANCER Jasonni VM 1 , Amadori A 2 , Gentile G 2 , Alesi L 2 1 Department of Obstetric and Gynecology, University of Messina. 2 Department of Obstetric and Gynecology, University of Bologna. TABLE OF CONTENTS 1. Abstract. 2. Introduction 2.1 epidermal growth factor (EGF). 2.2 Transforming growth factor alpha (TGF alpha). 2.3 Transforming growth factor beta (TGF beta). 2.4 Insulin-like growth factors (IGFs). 2.5 Fibroblast growth factors (FGFs). 2.6 Macrophage colony stimulating factor (MCSF). 3. Pahtogenesis of ovarian cancer . 4. Oncogenes and ovarian cancer . 5. Conclusion. 6. References. 1. ABSTRACT As with many ...

Centers for Disease Control and Prevention Epidemiology Program Office Case Studies in Applied Epidemiology No. 811-703 Oral Contraceptive Use and Ovarian Cancer Student's Guide Learning Objectives After completing this case study, the participant should be able to: G Outline the sequence of an epidemiologic analysis; G Discuss the biases of particular concern in case-control studies and ways to minimize their influence; G Describe why and when to use crude and adjusted odds ratios and 95% confidence intervals, and how to interpret them; and G Define and recognize effect modification and confounding. This case study was developed by Richard Dicker and Peter Layde in 1981. Current version updated by Richard Dicker with input from the EIS Summer Course instructors. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES ...

Tel. 972 8 934 Fax. 972 8 934 E-mail: Web page: Faculty of Biology 100 May 2004 101 Sarit Freimann Ada Dantes Liron Hirsh Aviva Blechman Marina Dolgin Ido Ben-Ami Ofer Merimsky Signal transduction based drug development for ovarian hyper-stimulation and anti- cancer treatment Department of Molecular Cell Biology Abraham Amsterdam 3713 4125 abraham.amsterdam@weizmann.ac.il www.weizmann.ac.il/mcb Regulation of the gonadotropic response through modulation of EGF-family proteins expression Gonadotropins play a crucial role in ovarian homeostasis and fertilization through the activation of the cAMP cascade. However, gonadotropin hyper-stimulation may be associated with elevated risk for ovarian cancer . It has been suggested, ...

497 A 60-year-old woman was admitted to the Cardiology Unit with a clinical picture of severe heart failure. Her medical history included a hysterectomy with bilateral oophorectomy performed 16 years previ- ously for ovarian cancer . On that occasion the patient had been submitted to chemotherapy with a subsequent complete remission of the disease persisting during follow-up. In particular, clinical and echo- graphic evaluation performed 2 months be- fore the current event excluded the presence of recurrent pelvic masses, and the serum levels of carbohydrate antigen (CA) 125, a tumor marker related to ovarian cancer 1 , were within the normal range (< 35 U/ml). During the month preceding hospitalization for heart failure, the patient complained of vague symptoms such as progressive effort dyspnea and generalized asthenia; a recur- rence of malignancy ...

Genetic Testing for Breast and Ovarian Cancer May 2002 Jennifer Silverman Stanford University, Stanford CA 94309 USA E-mail: jsilverman@stanford.edu Abstract Genetic testing for breast and ovarian cancer has been publicly available since the mid-1990 discovery of two breast/ ovarian cancer susceptibility genes named BRCA1 and BRCA2. Although many professionals say that genetic testing may be the best available preventative medicine breakthrough, controversy abounds over whether the medical benefits of BRCA1/2 mutation testing outweigh the psychological and financial costs. This study uses three models to analyze 104 women’s responses to a self-designed questionnaire: a logit regression model, an ordered probit regression model, and a cost effectiveness model. The regression models use questionnaire responses to learn how the benefits and costs of genetic testing affect a woman’s decision to ...

Int. J. Med. Sci. 2004 1(2): 116-125 116 International Journal of Medical Sciences ISSN 1449-1907 www.medsci.org 2004 1(2):116-125 ©2004 Ivyspring International Publisher. All rights reserved A Randomized Study of Epithelial Ovarian Cancer : Is Chemotherapy Useful after Complete Remission? Research paper Received: 2004.3.23 Accepted: 2004.5.17 Published: 2004.6.1 M.O. Nicoletto, S. Tumolo, C. Falci, M. Donach, E. Visonà, A. Rosabian, O. Nascimben, G.P. Cima, O. Vinante, P. Azzoni, M.V. Fiorentino GOCCNE Group (Gruppo Oncologico Cooperativo Clinico Nord-Est ovaio), Padua, Italy A A b b s s t t r r a a c c t t Objective . The aim of this study is to verify whether consolidation chemotherapy with Cisplatin improves disease-free survival and/or overall survival in patients affected by epithelial ovarian cancer . Methods ...

1 Published Quarterly Mangalore, S outh I ndia I SS N 0972-5997 Volume 3; I ssue 3; July-S eptember 2004 Epidemiology Risk Factors for Invasive Epithelial Ovarian Cancer by Histologic Subtype Jeffrey T. Quirk, Ph.D., Department of Biology and Health Services, 150 Cooper Science Hall, Edinboro University of Pennsylvania, Edinboro, PA, USA 16444 Nachimuthu Natarajan, M.S., Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY, USA 14263 Curtis J. Mettlin, Ph.D., Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY, USA 14263 Kirsten Barbara Moysich, Ph.D., Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY, USA 14263 Helen Swede, Ph.D., Connecticut Tumor Registry, Connecticut Department of Public Health, Hartford, CT, USA ...

© 2003 Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology • 2003:5 (2003) 308–314 • PII. S1110724303210032 • http://jbb.hindawi.com RESEARCH ARTICLE Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data Antonia Vlahou, 1,2 * John O. Schorge, 3 Betsy W. Gregory, 1,2 and Robert L. Coleman 3 1 Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA 23501, USA 2 Virginia Prostate Center, Eastern Virginia Medical School and Sentara Cancer Center, Norfolk, VA 23501, USA 3 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern, Dallas, TX 75390, USA Received 24 October 2002; ...

Descriptive Epidemiology of Ovarian Cancer in the United States, 1992-1997 CANCER (Supplement) 2003(May15);97/10:2615-2706. Descriptive Epidemiology of Ovarian Cancer in the United States, 1992-1997 Marc T. Goodman and Holly L. Howe Ovarian cancer is relatively uncommon, and therefore little has been published to date regarding racial or ethnic variations in the incidence or mortality of this malignancy. As the U.S. population becomes more diverse, the interest in health problems and disparities in outcomes among minority and economically disadvantaged groups will continue to increase. In this supplement, the authors focus on epidemiology, pathology and classification issues, multiple primary tumors, staging, and incidence and mortality for race/ethnic groups. The authors also focused on epidemiologic differences between borderline tumors of low malignant potential and carcinomas. ...

Cationic Liposome-Mediated E1A Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial By Gabriel N. Hortobagyi, Naoto T. Ueno, Weiya Xia, Su Zhang, Judith K. Wolf, Joe B. Putnam, Paul L. Weiden, Jie S. Willey, Mary Carey, Donna L. Branham, Joy Y. Payne, Stanley D. Tucker, Chandra Bartholomeusz, Robert G. Kilbourn, Robert L. De Jager, Nour Sneige, Ruth L. Katz, Pervin Anklesaria, Nuhad K. Ibrahim, James L. Murray, Richard L. Theriault, Vicente Valero, David M. Gershenson, Michael W. Bevers, Leaf Huang, Gabriel Lopez-Berestein, and Mien-Chie Hung Purpose: Preclinical studies have demonstrated that the adenovirus type 5 E1A gene is associated with antitu- mor activities by transcriptional repression of HER-2/neu and induction of apoptosis. Indeed, E1A gene therapy is known to induce regression of HER-2/neu–overex- pressing breast and ...

1 Risk Factors for Ovarian Cancer : An Overview McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa Page 2 2 Table of Contents Abstract 3 Introduction 4 Risk Factors 5 Family History. 6 Reproductive Factors 6 Hormone-Dependency. 7 Hormone Replacement Therapy (HRT). 7 Oral Contraceptive Pills (OCP) . 8 Lifestyle .. 9 Obesity and Physical Activity. 9 Diet. 10 Cigarette Smoking.. 10 Environmental Factors .. 12 Occupational Exposure 12 Environmental Contaminants 12 Conclusion.. 13 Acknowledgements. 15 References 16 Page 3 3 Abstract Ovarian cancer is the fifth most frequent cancer among women and is the leading cause of gynaecological cancer deaths in North America. Although ...

Cancer in Rhode Island 12-1 OVARIAN CANCER Ovarian cancer originates in the inner tissues or outer lining of the ovaries, or female reproductive organs. Ovarian cancer can be divided into three categories: epithelial carcinoma, germ cell cancer , and stromal cancer . Epithelial carcinomas are tumors that originate in the epithelial cells that form the lining of the ovaries; it is the most common type of ovarian cancer . Germ cell cancer originates in the cells that are to become the egg cells that are released each month from the ovary. It is not common (only about 5% of ovarian cancer cases) and is usually found in younger women. Stromal cell cancer originates in the cells that make up the tissues that hold the ovary together; it also accounts for only about 5% of ovarian cancer cases. (RICAN) Ovarian cancer is the sixth most commonly diagnosed cancer among RI females ...

Random thoughts on Ovarian Cancer Why is ovarian cancer so hard to detect? Actually, most cancers are difficult to detect. Most of the time a cancer is not found until it produces some type of symptom and is already fairly advanced. This usually requires that the cancer 1) be fairly large so that it affects the function of an organ (e.g. ovarian cancer ), 2) erode into a mucosal surface and cause bleeding (e.g. colon cancer ), or 3) cause pain (e.g. bone metastases). Ovarian cancer does not erode into organs and, therefore, does not cause any unusual bleeding from the colon or vagina. As it progresses ovarian cancer spreads along the surface of organs in the abdomen and does not produce any type of pain. It is only when the volume of the cancer is great enough to cause some abdominal distension that it makes itself obvious. Since the female pelvis is designed to accommodate large objects ...

NMT B B R R I I E E F F S S New Medical Therapies Ovarian Cancer O varian cancer originates in tissue exclusive to the ovary, including sur- face epithelial cells, germ cells and the sex cord-stromal cells. Most epithelial ovarian tumors are benign, including serous adeno- mas, mucinous adenomas and Brenner tumors. Malignant epithelial ovarian carcino- mas comprise 85%-90% of all ovarian cancer . Ovarian cancer accounts for 4% of all female cancers, making it the fifth most common cancer among women, except for non-melanoma skin cancers, and the fourth ranked cause of cancer deaths. Although the incidence of ovarian cancer has decreased since 1991, there will be about 25,580 new cases of ovarian cancer and about 16,090 deaths from ovarian cancer in the U.S. during 2004, ...

taxanes_protocol_10-jan-2001_final-draft.doc 1 NYCRIS Regional Audit Project Use of Taxanes for Ovarian Cancer Draft PROTOCOL Page 2 taxanes_protocol_10-jan-2001_final-draft.doc 2 1. Background 1.1 Use of taxanes There has, in recent years, been an issue of equity of access to the use of taxanes for patients with ovarian cancer across the UK and variation has existed in the decisions made regarding the use of taxanes by Health Authority Commissioners. There are two taxane drugs available in the UK, docetaxel (Taxotere) and paclitaxel (Taxol), although Taxotere is not currently licensed for ovarian cancer . They both cost about £1,500 per course of treatment and each patient may need up to six courses. Because of this high cost, it is thought that most patients in the past received taxanes as a second line treatment mainly under ...

115 www.onk.ns.ac.yu/Archive August 10, 2004 Pathogenesis of malignant ascites in ovarian cancer patients Zorica StanojeviÊ 1 , Gorana RanËiÊ 2 , Stojan RadiÊ 1 , Natapa PotiÊ-ZeËeviÊ 1 , Biljana –oreviÊ 3 , Milan MarkoviÊ 1 , Ilinka Todorovska 1 ABSTRACT Peritonitis carcinomatosa, indicating the presence of malignant cells in the peritoneal cavity, is a well- known complication of malignant disease. The collection of intraperitoneal fluid in a patient with ovarian cancer is most likely due to intraperitoneal spread of disease. The recognition of small quantities of intraperitoneal fluid may have staging and prognostic significance, while symptomatic large collections may reflect end-stage disease, which permits only palliative therapeutic options. In this paper, we dis- cussed the ...

Gyn-Oncology Case Presentation David Engle MD Dept. of Ob/Gyn University of TN- Memphis Page 2 Case • 62yo SEA Female G2P2 • Pt presented to PCP complaning of recent weight gain, and feeling of Abdominal Pressure. • TVUSG showed a Complex R adnexal mass that measured 16.7cm, with mixed solid and cystic components. • CA125=Unk? Page 3 More • In OR Pt had large Ovarian Mass, with a frozen section showing-Poorly Diff. Serous Tumor. • At this time a TAH/BSO/Stagging was perfomed • Staging: Pelvic & Periaortic LND; Diaphram Scrapping, Omentectomy, Bx of Bil Pericolic gutters, side walls,and ant and post cul-de-sac Page 4 More Again • Pt remained hospitalized x5 ...

AICR Ever Green Ever Healthy Feature November 2003 Topic: Cancer Ovarian Cancer by the American Institute for Cancer Research Ovarian cancer is one of the five most deadly cancers among women in developed countries. Unfortunately, ovarian cancer is difficult to detect through current tests and screenings. Often, it produces no clear symptoms until late in development. But now several different studies show that a mostly plant- based diet can lower risk of ovarian cancer in multiple ways. In four of the studies that took place within the last two years, more vegetables and fruits reduced the risk of ovarian cancer by one-third to two-thirds. Part of the reason may be the variety of phytochemicals in vegetables and fruits. Some of these substances reveal an ability to fight a broad range of cancers in laboratory tests. Do Not Forget Fiber Fiber in vegetables, ...

New and Emerging Technology Briefing Gemcitabine for recurrent ovarian cancer July 2003 Horizon Scanning Review Early assessments of new or emerging technologies contain time-limited information and should be used with due caution. Not to be used for commercial purposes National Horizon Scanning Centre Page 2 National Horizon Scanning Centre GEMCITABINE in Ovarian Cancer July 2003 1 Gemcitabine for recurrent ovarian cancer Summary Gemcitabine (Gemzar) in combination with carboplatin (Paraplatin) is in phase III clinical trials for women with recurrent ovarian cancer who have failed prior platinum-based therapy at least 6 months after discontinuation. A phase III trial has been completed but no results are yet available. A published phase II trial of ...

New and Emerging Technology Briefing 90 Y-muHMFG1 for ovarian cancer July 2003 Horizon Scanning Review Early assessments of new or emerging technologies contain time-limited information and should be used with due caution. Not to be used for commercial purposes National Horizon Scanning Centre Page 2 National Horizon Scanning Centre 90 Y-muHMFG1 July 2003 1 90 Y-muHMFG1 for ovarian cancer Summary 90 Y-muHMFG1 consists of a murine monoclonal antibody (HMFG1) chemically linked to the radioactive isotope yttrium-90. HMFG1 targets and binds to a tumour antigen expressed on the surface of epithelial tumour cells. R1549 (a 90 Y-muHMFG1 commercial product from Antisoma and Roche) is currently in phase III trials ...

Management Options for Women with a Hereditary Predisposition to Ovarian Cancer Evidence Summary Report #4-4 B Rosen, J Kwon, M Fung Kee Fung, A Gagliardi of the Cancer Care Ontario Surgical Oncology Network, and members of the Gynecology Cancer Disease Site Group ORIGINAL EVIDENCE SUMMARY: September 2, 2003 MOST RECENT LITERATURE SEARCH: June 2004 NEW EVIDENCE ADDED TO EVIDENCE SUMMARY: June 2004 New evidence found by update searches since completion of the original evidence summary is consistent with the original recommendations. An evidence summary report is a systematic overview of the best evidence available on a specific clinical question when there is insufficient high-quality evidence on which to base a practice guideline. SUMMARY Question What are the management options for women with a hereditary predisposition to ovarian cancer ? Outcomes of ...

1 One of only six in Australia, a Palm laser dissection microscope has been installed at Prince Henry’s Institute. It is the only microscope of its kind in Australia to be used for ovarian cancer research. The microscope uses a technique called laser pressure catapulting – using the force of light to lift up samples of a cell into a sterile tube for analysis. This means researchers can isolate single or groups of cells from a wide variety of animal and human tissue samples. “This cutting edge technology is an enormous advance for our institute. There is no limitation in the way this machine can be used to under-stand normal and diseased states,” said Professor Evan Simpson, Director of Prince Henry’s Institute. “In regards to ovarian cancer , the Palm laser dissection microscope will allow us to look at the ...

1 Dr Martin Oehler, MD PhD has commenced as the National Australia Bank Research Fellow with the Ovarian Cancer Research Foundation . Martin will continue the Foundation’s ovarian cancer research to find an early detection test for this disease. Born and educated in Germany, Dr Oehler’s extensive research and medical career includes postdoctoral positions at Baylor College of Medicine in Houston, Texas, USA and at the Institute of Molecular Medicine in Oxford, UK. In Australia, Dr Oehler has embarked upon a Fellowship specialising in gynaecological oncology and com- pleted his first year as a Clinical Fellow in the Department of Gyn- aecological Oncology at Westmead Hospital in Sydney. Having published 40 papers in the fields of gynaecology and cancer research, Dr Oehler brings a wealth of expertise to this position. ...

Diagnosis of Ovarian Cancer Based on Mass Spectra of Blood Samples * Hong Tang Computer Science and Eng. University of South Florida Tampa, fl 33620 htang2@csee.usf.edu Yelena Mukomel Computer Science and Eng. University of South Florida Tampa, fl 33620 mukomel@csee.usf.edu Eugene Fink Language Technologies Carnegie Mellon University Pittsburgh, pa 15213 e.fink@cs.cmu.edu Abstract – The early detection of cancer is crucial for successful treatment, and medical researchers have in- vestigated a number of early-diagnosis techniques. Re- cently, they have discovered that some cancers affect the concentration of certain molecules in the blood, which allows early diagnosis by analyzing the blood mass spec- trum. Researchers have developed several techniques for ...

Corporate Medical Policy Oophorectomy, Prophylactic for Ovarian Cancer File Name: oophorectomy_prophylactic_for_ovarian_cancer Policy Number: SUR6480 Origination: 11/1995 Last Review: 8/2003 Next Review: 8/2005 Active policy, no longer scheduled for routine literature review. Description of Procedure or Service Prophylactic oophorectomy is the surgical removal of both ovaries to prevent the development of ovarian cancer in women who are at high risk for the disease. Policy Active policy, no longer scheduled for routine literature review. BCBSNC will provide coverage for Oophorectomy, Prophylactic for Ovarian Cancer when it is deter- mined to be medically necessary because the medical criteria and guidelines shown below are met. Benefits Application Please refer to certificate for availability of benefits. ...

D105 Aberrant methylation at pro-apoptotic genes in ovarian cancer is associated with clinical outcome Jens Teodoridis, Gillian Gifford, Jorge Curto-Garcia, Jim Paul, Paul Vasey, Gordon Strathdee and Robert Brown CRUK Beatson Laboratories, Glasgow University We have examined whether genes involved in response of cells to DNA damage can become aberrantly methylated in stage III/IV epithelial ovarian tumours and whether this can predict clinical outcome. We grouped the genes depending on their function (DNA repair, cell cycle control, apoptosis and all) and determined whether methylation was associated with progression-free survival of patients following chemotherapy. Overall, 61% of tumours showed methylation of at least one of the 16 genes examined. Of the four groups of genes examined, only methylation of the pro-apoptotic genes was significantly associated with poor progression-free ...

Diagnosis of Ovarian Cancer Based on Mass Spectrum of Blood Samples by Hong Tang A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Computer Science Department of Computer Science and Engineering College of Engineering University of South Florida Co-Major Professor: Eugene Fink, Ph.D. Co-Major Professor: Lihua Li, Ph.D. Member: Dmitry B. Goldgof, Ph.D. Date of Approval: July 22, 2003 Keywords: Data Mining, Medical Application, Decision Trees, Support Vector Machines, Neural Networks. c Copyright 2003, Hong Tang Page 2 Acknowledgements I am grateful to my faculty supervisors, Eugene Fink and Lihua Li, for their help and support. I thank Dmitry Goldgof for his valuable comments and suggestions. I also appreciate the help of my fellow graduate students: Yong Chu, Jianli Gong, Yelena ...

4 MJA Vol 177 1 July 2002 EDITORIALS The Medical Journal of Australia ISSN: 0025-729X 1 July 2002 177 1 4-4 ©The Medical Journal of Australia 2002 www.mja.com.au Editorials A good screening tool seems to offer the best hope, but meanwhile best possible care includes definitive staging and surgery by experienced specialist teams O VARIAN CANCER is the leading cause of death from gynaecological cancer in Australia, and indeed most West- ern countries. In the absence of effective primary prevention strategies and screening for early disease, the best possible management of patients with suspected or established ovar- ian cancer assumes critical importance if inroads are to be made in reducing morbidity and mortality from this disease. In this issue of the Journal ( page 11 ), Grossi et al have reviewed the management of women with ovarian ...

MJA Vol 178 16 June 2003 655 CANCER SCREENING The Medical Journal of Australia ISSN: 0025-729X 16 June 2003 178 12 655-656 ©The Medical Journal of Australia 2003 www.mja.com.au Cancer screening E PITHELIAL OVARIAN MALIGNANCIES occur in over 1000 Australian women annually, and more than 75% of these women eventually succumb to the disease. 1 Women with early-stage ovarian cancer have a 5-year survival rate of over 80%, suggesting that early detection may improve survival. To date, it has not been established whether benign (assessed histologically as non-invasive) or borderline ovarian tumours are premalignant. In the absence of a precancerous lesion, the goal of screening is the detection of preclinical disease. Screening tests A number of screening tests have been evaluated or are being evaluated currently. ...